Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.
Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS.
Bai Y, et al. Among authors: jhaveri kd.
Kidney Int. 2021 Dec;100(6):1214-1226. doi: 10.1016/j.kint.2021.08.022. Epub 2021 Sep 15.
Kidney Int. 2021.
PMID: 34534550
Free PMC article.